RxDoctor Payments Data

Rajeev Krishan, MD

Gastroenterology · Bakersfield, CANPI 1033124854

Payments from drug & device makers

$190,383in general payments, 2019–2025

Across 124 payments — averaging $1535.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$174K
  • Braintree Laboratories, Inc.$14K
  • Boston Scientific$2K
  • Johnson & Johnson$304
  • Madrigal Pharmaceuticals$125
  • Janssen Scientific Affairs, LLC$124
  • plus $113 from 4 others
$15,034in research payments, 2019–2025

Across 2 payments — averaging $7517.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$15K

What the payments were for

  • Food & beverage$2,12189%
  • Education$25311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$190,383 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$185,910
Medicare patients
588
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$170,297
LinzessLinaclotide236$129,047
Pantoprazole Sodium2,303$16,533
Mesalamine ErMesalamine11$9,082
LoperamideLoperamide Hcl210$7,524
Dexlansoprazole DrDexlansoprazole19$4,661
Ursodiol32$3,766
Balsalazide Disodium25$3,206
Mesalamine18$2,770
Esomeprazole Magnesium98$2,552
Ondansetron OdtOndansetron93$2,240
Lubiprostone23$1,914
Dicyclomine Hcl99$1,846
Sucralfate62$1,799
Omeprazole193$1,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$21$129,047236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →